middle.news
How Island Pharmaceuticals’ Dual Antiviral Strategy Could Reshape Infectious Disease Treatment
9:10am on Thursday 24th of July, 2025 AEST
•
Healthcare
Read Story
How Island Pharmaceuticals’ Dual Antiviral Strategy Could Reshape Infectious Disease Treatment
9:10am on Thursday 24th of July, 2025 AEST
Key Points
Positive Phase 2a/b clinical trial results for ISLA-101 in dengue fever
Significant reduction in viral load and symptoms in preventative cohort
Asset purchase agreement secured for Galidesivir antiviral program
Capital raise of $3.6 million strengthens balance sheet
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Island Pharmaceuticals (ASX:ILA)
OPEN ARTICLE